Published in JAMA Dermatol on June 01, 2013
Video-mosaicing of reflectance confocal images for examination of extended areas of skin in vivo. Br J Dermatol (2014) 0.92
Intraoperative real-time reflectance confocal microscopy for guiding surgical margins of lentigo maligna melanoma. Dermatol Surg (2015) 0.75
[Modern diagnostic procedures in dermatological oncology]. Pathologe (2015) 0.75
Dermoscopy-guided reflectance confocal microscopy of skin using high-NA objective lens with integrated wide-field color camera. Proc SPIE Int Soc Opt Eng (2016) 0.75
Very Rare Amelanotic Lentigo Maligna Melanoma with Skull Roof Invasion. Open Access Maced J Med Sci (2017) 0.75
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med (2015) 4.64
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Cutaneous melanoma. Lancet (2005) 3.94
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
DNAzyme targeting c-jun suppresses skin cancer growth. Sci Transl Med (2012) 3.09
The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol (2004) 2.99
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med (2011) 2.60
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
Keystone flap reconstruction of primary melanoma excision defects of the leg-the end of the skin graft? Ann Surg Oncol (2008) 2.36
False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res (2009) 2.26
Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol (2009) 2.26
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. J Invest Dermatol (2008) 2.13
Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol (2012) 2.13
Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol (2010) 2.06
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol (2009) 1.82
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80
Border detection in dermoscopy images using statistical region merging. Skin Res Technol (2008) 1.79
In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol (2012) 1.79
Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions. Arch Dermatol (2006) 1.79
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer (2003) 1.68
Absence of distinguishing senescence traits in human melanocytic nevi. J Invest Dermatol (2012) 1.65
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 1.65
Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol (2008) 1.64
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol (2012) 1.63
Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst (2014) 1.61
Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol (2004) 1.57
The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J Invest Dermatol (2010) 1.55
Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished? Pathology (2002) 1.50
Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet (2013) 1.50
Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center. Ann Surg Oncol (2014) 1.50
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist (2014) 1.50
In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol (2014) 1.48
Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. Ann Surg Oncol (2012) 1.48
Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population. Ann Surg Oncol (2011) 1.48
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg (2012) 1.46
Surgical strategies and histopathologic issues in the management of lentigo maligna. Ann Surg Oncol (2009) 1.44
Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions. Am J Dermatopathol (2003) 1.44
The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck (2004) 1.42
Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology (2009) 1.42
Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res (2013) 1.41
Technologies for the diagnosis of primary melanoma of the skin. Med J Aust (2006) 1.40
Treatment and prognostic significance of positive interval sentinel nodes in patients with primary cutaneous melanoma. Ann Surg Oncol (2011) 1.40
MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A (2011) 1.39
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol (2007) 1.38
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer (2003) 1.38
Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol (2003) 1.38
Tumours associated with BAP1 mutations. Pathology (2013) 1.35
Desmoplastic melanoma: a diagnostic trap for the unwary. Pathology (2004) 1.29
The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology (2006) 1.25
Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg Pathol (2007) 1.24
A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol (2005) 1.24
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab (2003) 1.22
Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv Anat Pathol (2009) 1.22
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res (2014) 1.22
Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer (2008) 1.22
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother (2003) 1.21
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther (2012) 1.21
SOX2 contributes to melanoma cell invasion. Lab Invest (2011) 1.21
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res (2013) 1.18
Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer (2010) 1.16
IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell (2010) 1.13
Cutaneous melanoma in the era of molecular profiling. Lancet (2009) 1.10
Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol (2014) 1.10
Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Ann Surg Oncol (2007) 1.10
Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol (2006) 1.08